Search Results

Now showing 1 - 9 of 9
  • Item
    Dicyclohexylbis(naphthalen-1-ylmethyl)phosphonium chloride chloroform disolvate
    (Chester : International Union of Crystallography, 2012) Gowrisankar, S.; Neumann, H.; Spannenberg, A.; Beller, M.
    In the title solvated phosphonium salt, C34H40P+·Cl -·2CHCl3, the two cyclohexyl and two 1-naphthylmethyl groups at the P atom are in a distorted tetrahedral arrangement [105.26 (6)-113.35 (6)°]. Both cyclohexyl rings adopt a chair conformation. The dihedral angle between the naphthyl ring systems is 74.08 (3)°.
  • Item
    (η6-Benzene)(carbonato-κ2O,O') [dicyclohexyl(naphthalen-1-ylmethyl)phosphanejP] ruthenium(II) chloroform trisolvate
    (Chester : International Union of Crystallography, 2014) Gowrisankar, S.; Neumann, H.; Spannenberg, A.; Beller, M.
    The title compound, [Ru(CO3)(η6-C 6H6){(C6H11)2P(CH 2-C10H7)}]-3CHCl3, was synthesized by carbonation of [RuCl2-(η6-C6H 6){(C6H11)2P(CH2C 10H7)}] with NaHCO3in methanol at room temperature. The RuIIatom is surrounded by a benzene ligand, a chelating carbonate group and a phosphane ligand in a piano-stool configuration. The crystal packing is consolidated by C-H⋯O and C-H⋯Cl hydrogen-bonding interactions between adjacent metal complexes and between the complexes and the solvent molecules. The asymmetric unit contains one metal complex and three chloroform solvent molecules of which only one was modelled. The estimated diffraction contributions of the other two strongly disordered chloroform solvent molecules were substracted from the observed diffraction data using the SQUEEZE procedure in PLATON.
  • Item
    (η6-Benzene)dichlorido(chlorodicyclohexylphosphane-κp) ruthenium(II) chloroform monosolvate
    (Chester : International Union of Crystallography, 2014) Gowrisankar, S.; Neumann, H.; Spannenberg, A.; Beller, M.
    The title compound, [RuN4(-6-C6H6) (C12H22ClP)]-CHCl3, was prepared by reaction of [RuN 4(-6-C6H6)]2 with chlorodicyclohexyl phosphane in CHCl3 at 323 K under argon. The RuII atom is surrounded by one arene ligand, two Cl atoms and a phosphane ligand in a piano-stool geometry. The phosphane ligand is linked by the P atom, with an Ru-P bond length of 2.3247 (4) Å. Both cyclohexyl rings at the P atom adopt a chair conformation. In the crystal, the RuII complex molecule and the chloroform solvent molecule are linked by a bifurcated C-H⋯(Cl,Cl) hydrogen bond. Intramolecular C-H⋯Cl hydrogen bonds are also observed.
  • Item
    2,6-Bis[(S)-4-benzyl-4,5-dihydro-1,3-oxazol-2-yl]pyridine
    (Chester : International Union of Crystallography, 2011) Möller, K.; Junge, K.; Spannenberg, A.; Beller, M.
    The commercially available title compound, C25H 23N3O2, has been known since 1993 [Nesper et al. (1993). Helv. Chim. Acta, 76, 2239-2249], but has not been structurally characterized until now. In the free ligand, the N atoms of both oxazoline rings point in opposite directions. The phenyl rings make dihedral angles of 30.56 (5) and 84.57 (3)° with the pyridine ring and 72.85 (3)° with each other.
  • Item
    Catalytic hydrogenation of carboxylic acid esters, amides, and nitriles with homogeneous catalysts
    (Washington, DC : American Chemical Society, 2014) Werkmeister, S.; Junge, K.; Beller, M.
    This review describes the catalytic reduction of amides, carboxylic acid esters and nitriles with homogeneous catalysts using molecular hydrogen as an environmental friendly reducing agent.
  • Item
    Novel ruthenium-catalyst for hydroesterification of olefins with formates
    (London [u.a.] : Royal Society of Chemistry, 2014) Profir, I.; Beller, M.; Fleischer, I.
    An alternative ruthenium-based catalyst for the hydroesterification of olefins with formates is reported. The good activity of our system is ensured by the use of a bidentate P,N-ligand and ruthenium dodecacarbonyl. A range of formates can be used for selective alkoxycarbonylation of aromatic olefins. In addition, the synthesis of selected aliphatic esters is realized. The proposed active ruthenium complex has been isolated and characterized.
  • Item
    Selective reductive amination of aldehydes from nitro compounds catalyzed by molybdenum sulfide clusters
    (Cambridge : RSC, 2017) Pedrajas, E.; Sorribes, I.; Junge, K.; Beller, M.; Llusar, R.
    Secondary amines are selectively obtained from low value starting materials using hydrogen and a non-noble metal-based catalyst. The reductive amination of aldehydes from nitroarenes or nitroalkanes is efficiently catalyzed by a well-defined diamino molybdenum sulfide cluster in a one-pot homogeneous reaction. The integrity of the molecular cluster catalyst is preserved along the process.
  • Item
    The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells
    (London : BioMed Central, 2014) Kretzschmar, C.; Roolf, C.; Langhammer, T.-S.; Sekora, A.; Pews-Davtyan, A.; Beller, M.; Frech, M.J.; Eisenlöffel, C.; Rolfs, A.; Junghanss, C.
    Background: Prognosis of adult patients suffering from acute lymphoblastic leukemia (ALL) is still unsatisfactory. Targeted therapy via inhibition of deregulated signaling pathways appears to be a promising therapeutic option for the treatment of ALL. Herein, we evaluated the influence of a novel arylindolylmaleimide (PDA-66), a potential GSK3β inhibitor, on several ALL cell lines.Methods: ALL cell lines (SEM, RS4;11, Jurkat and MOLT4) were exposed to different concentrations of PDA-66. Subsequently, proliferation, metabolic activity, apoptosis and necrosis, cell cycle distribution and protein expression of Wnt and PI3K/Akt signaling pathways were analyzed at different time points.Results: PDA-66 inhibited the proliferation of ALL cells significantly by reduction of metabolic activity. The 72 h IC50 values ranged between 0.41 to 1.28 μM PDA-66. Additionally, caspase activated induction of apoptosis could be detected in the analyzed cell lines. PDA-66 influenced the cell cycle distribution of ALL cell lines differently. While RS4;11 and MOLT4 cells were found to be arrested in G2 phase, SEM cells showed an increased cell cycle in G0/1 phase.Conclusion: PDA-66 displays significant antileukemic activity in ALL cells and classifies as candidate for further evaluation as a potential drug in targeted therapy of ALL.